Researchers Studying Two Point-of-Care Tests to Gauge PGx Response to Anti-Platelet Drugs
August 11, 2010
Researchers Studying Two Point-of-Care Tests to Gauge PGx Response to Anti-Platelet Drugs
Spartan Bioscience and Nanosphere are each working with academic research groups to determine the utility of their CYP2C19 tests for gauging response to Plavix at the point of care.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Spartan Bioscience's CE-Marked CYP2C19 Test Will Also Be Submitted to the FDA
December 22, 2010 / Pharmacogenomics Reporter - Spartan Bioscience Building Evidence for Point-of-Care PGx Testing to Guide Antiplatelet Therapy
March 13, 2013 / Pharmacogenomics Reporter - FDA Clears Nanosphere's CYP2C19 Test to Guide Therapeutic Strategy, Not Predict Response
November 14, 2012 / Pharmacogenomics Reporter - Canadian Team Validates Spartan's Point-of-Care CYP2C19 Test to Personalize Anti-Platelet Treatment
November 30, 2011 / Pharmacogenomics Reporter - Study: Higher Plavix Dose Doesn't Improve Response for CYP2C19*2 Carriers; Effient May Be Best Option
April 4, 2012 / Pharmacogenomics Reporter